{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:47:46Z","timestamp":1790736466854,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.jpet.2025.103745","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T16:04:57Z","timestamp":1759939497000},"page":"103745","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Anti-IGF-1R antisense oligonucleotide CT102: A promising therapeutic agent for graves' ophthalmopathy"],"prefix":"10.1016","volume":"392","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-7633-3499","authenticated-orcid":false,"given":"Yuting","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gengshen","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jpet.2025.103745_bib1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4103\/tjo.tjo_51_21","article-title":"Thyroid eye disease: from pathogenesis to targeted therapies","volume":"12","author":"Yoon","year":"2022","journal-title":"Taiwan J Ophthalmol"},{"issue":"4","key":"10.1016\/j.jpet.2025.103745_bib2","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/S2213-8587(14)70225-6","article-title":"Iodine deficiency and thyroid disorders","volume":"3","author":"Zimmermann","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"16","key":"10.1016\/j.jpet.2025.103745_bib3","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1056\/NEJMra1510030","article-title":"Graves\u2019 disease","volume":"375","author":"Smith","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jpet.2025.103745_bib4","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S0002-9394(14)70276-4","article-title":"Clinical features of Graves' ophthalmopathy in an incidence cohort","volume":"121","author":"Bartley","year":"1996","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"10.1016\/j.jpet.2025.103745_bib5","doi-asserted-by":"crossref","first-page":"E740","DOI":"10.1210\/jc.2011-2514","article-title":"Increased expression of TSH receptor by fibrocytes in thyroid-associated ophthalmopathy leads to chemokine production","volume":"97","author":"Gillespie","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.jpet.2025.103745_bib6","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.survophthal.2009.06.009","article-title":"Immunopathogenesis of thyroid eye disease: emerging paradigms","volume":"55","author":"Naik","year":"2010","journal-title":"Surv Ophthalmol"},{"issue":"4","key":"10.1016\/j.jpet.2025.103745_bib7","doi-asserted-by":"crossref","first-page":"G43","DOI":"10.1530\/EJE-21-0479","article-title":"The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy","volume":"185","author":"Bartalena","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"10.1016\/j.jpet.2025.103745_bib8","doi-asserted-by":"crossref","first-page":"D27","DOI":"10.1530\/EJE-19-0389","article-title":"Will biological agents supplant systemic glucocorticoids as the first-line treatment for thyroid-associated ophthalmopathy?","volume":"181","author":"Smith","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"10.1016\/j.jpet.2025.103745_bib9","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1530\/EJE-14-0712","article-title":"Intravenous glucocorticoid therapy for Graves' ophthalmopathy and acute liver damage: an epidemiological study","volume":"172","author":"Sisti","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1016\/j.jpet.2025.103745_bib10","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1210\/jcem.87.1.8164","article-title":"Orbital fibroblast heterogeneity may determine the clinical presentation of thyroid-associated ophthalmopathy","volume":"87","author":"Smith","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.jpet.2025.103745_bib11","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1210\/er.2018-00066","article-title":"Insulin-like growth factor-I receptor and thyroid-associated ophthalmopathy","volume":"40","author":"Smith","year":"2019","journal-title":"Endocr Rev"},{"key":"10.1016\/j.jpet.2025.103745_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107502","article-title":"TSH\/IGF1 receptor crosstalk: mechanism and clinical implications","volume":"209","author":"Krieger","year":"2020","journal-title":"Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.jpet.2025.103745_bib13","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1910434","article-title":"Teprotumumab for the treatment of active thyroid eye disease","volume":"382","author":"Douglas","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpet.2025.103745_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.medidd.2020.100075","article-title":"Biologics vs. small molecules: drug costs and patient access","volume":"9","author":"Makurvet","year":"2021","journal-title":"Med Drug Discov"},{"issue":"2","key":"10.1016\/j.jpet.2025.103745_bib15","doi-asserted-by":"crossref","first-page":"536","DOI":"10.3390\/molecules27020536","article-title":"Small drugs, huge impact: the extraordinary impact of antisense oligonucleotides in research and drug development","volume":"27","author":"Quemener","year":"2022","journal-title":"Molecules"},{"issue":"4","key":"10.1016\/j.jpet.2025.103745_bib16","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s40259-024-00665-2","article-title":"Mechanisms of action of the US Food and Drug Administration-approved antisense oligonucleotide drugs","volume":"38","author":"Sang","year":"2024","journal-title":"BioDrugs"},{"issue":"34","key":"10.1016\/j.jpet.2025.103745_bib17","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.2217\/fon-2023-0872","article-title":"Preclinical and phase I studies of an antisense oligonucleotide drug targeting IGF-1R in liver cancer","volume":"20","author":"Li","year":"2024","journal-title":"Future Oncol"},{"issue":"4","key":"10.1016\/j.jpet.2025.103745_bib18","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/WNO.0000000000001134","article-title":"Teprotumumab in clinical practice: recommendations and considerations from the OPTIC trial investigators","volume":"41","author":"Douglas","year":"2021","journal-title":"J Neuroophthalmol"},{"key":"10.1016\/j.jpet.2025.103745_bib19","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.2147\/JIR.S339483","article-title":"MiR-143 Targets IGF-1R to suppress autoimmunity in thyroid-associated ophthalmopathy","volume":"15","author":"Tang","year":"2022","journal-title":"J Inflamm Res"},{"issue":"12","key":"10.1016\/j.jpet.2025.103745_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0114420","article-title":"MiR-143 and MiR-145 regulate IGF1R to suppress cell proliferation in colorectal cancer","volume":"9","author":"Su","year":"2014","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.jpet.2025.103745_bib21","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods (San Diego, Calif)"},{"issue":"2","key":"10.1016\/j.jpet.2025.103745_bib22","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/archopht.1993.01090020051022","article-title":"The initial clinical characteristics of graves' orbitopathy vary with age and sex","volume":"111","author":"Kendler","year":"1993","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jpet.2025.103745_bib23","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.omtn.2023.04.028","article-title":"Modified ASO conjugates encapsulated with cytidinyl\/cationic lipids exhibit more potent and longer-lasting anti-HCC effects","volume":"32","author":"Pan","year":"2023","journal-title":"Mol Ther Nucl Acids"},{"issue":"5","key":"10.1016\/j.jpet.2025.103745_bib24","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1872-034X.2007.00055.x","article-title":"Inhibition of hepatocellular carcinoma growth by antisense oligonucleotides to type I insulin-like growth factor receptor in vitro and in an orthotopic model","volume":"37","author":"Lin","year":"2007","journal-title":"Hepatol Res"},{"issue":"12","key":"10.1016\/j.jpet.2025.103745_bib25","doi-asserted-by":"crossref","first-page":"4920","DOI":"10.1021\/acs.molpharmaceut.9b00800","article-title":"Construction of a targeting nanoparticle of 3\u2032,3\u2033-bis-peptide-siRNA conjugate\/mixed lipid with postinserted DSPE-PEG2000-cRGD","volume":"16","author":"Zhang","year":"2019","journal-title":"Mol Pharm"},{"issue":"12","key":"10.1016\/j.jpet.2025.103745_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0145587","article-title":"The insulin-like growth factor system in the long-lived naked mole-rat","volume":"10","author":"Brohus","year":"2015","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.jpet.2025.103745_bib27","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1210\/jcem-61-5-1001","article-title":"Anti-thyroid peroxidase antibody in patients with autoimmune thyroid disease: possible identity with anti-microsomal antibody","volume":"61","author":"Portmann","year":"1985","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jpet.2025.103745_bib28","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/182472","article-title":"Thyroid autoantibodies in pregnancy: their role, regulation and clinical relevance","volume":"2013","author":"Balucan","year":"2013","journal-title":"J Thyroid Res"},{"issue":"2","key":"10.1016\/j.jpet.2025.103745_bib29","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ecl.2021.12.004","article-title":"2022 update on clinical management of graves disease and thyroid eye disease","volume":"51","author":"Hoang","year":"2022","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.jpet.2025.103745_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2023.109436","article-title":"Development and application of animal models to study thyroid-associated ophthalmopathy","volume":"230","author":"Shen","year":"2023","journal-title":"Exp Eye Res"},{"issue":"6","key":"10.1016\/j.jpet.2025.103745_bib31","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.4049\/jimmunol.181.6.4397","article-title":"Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: A tale of two antigens implicated in Graves\u2019 disease","volume":"181","author":"Tsui","year":"2008","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.jpet.2025.103745_bib32","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1007\/s10792-021-01706-3","article-title":"Teprotumumab (Tepezza): from the discovery and development of medicines to USFDA approval for active thyroid eye disease (TED) treatment","volume":"41","author":"Ali","year":"2021","journal-title":"Int Ophthalmol"},{"issue":"4","key":"10.1016\/j.jpet.2025.103745_bib33","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1210\/clinem\/dgac627","article-title":"Teprotumumab-related hyperglycemia","volume":"108","author":"Amarikwa","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.jpet.2025.103745_bib34","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.ophtha.2021.10.017","article-title":"Teprotumumab efficacy, safety, and durability in longer-duration thyroid eye disease and re-treatment: OPTIC-X study","volume":"129","author":"Douglas","year":"2022","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.jpet.2025.103745_bib35","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1002\/ohn.174","article-title":"Prospective assessment of otologic adverse events due to teprotumumab: preliminary results","volume":"168","author":"Kay-Rivest","year":"2023","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"2","key":"10.1016\/j.jpet.2025.103745_bib36","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/lary.31763","article-title":"The impact of monoclonal antibody usage on hearing outcomes: a systematic review","volume":"135","author":"Arya","year":"2025","journal-title":"Laryngoscope"},{"key":"10.1016\/j.jpet.2025.103745_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1006304","article-title":"A perspective on oligonucleotide therapy: Approaches to patient customization","volume":"13","author":"Thakur","year":"2022","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.jpet.2025.103745_bib38","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s43856-023-00419-1","article-title":"Possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disorders","volume":"4","author":"Lauffer","year":"2024","journal-title":"Commun Med"},{"issue":"10","key":"10.1016\/j.jpet.2025.103745_bib39","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1038\/s41591-024-03197-y","article-title":"Antisense oligonucleotide therapy in an individual with KIF1A-associated neurological disorder","volume":"30","author":"Ziegler","year":"2024","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.jpet.2025.103745_bib40","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1038\/s41591-023-02335-2","article-title":"Personalized antisense oligonucleotides \u2018for free, for life\u2019 \u2014 the n-Lorem foundation","volume":"29","author":"Gleeson","year":"2023","journal-title":"Nat Med"},{"issue":"7971","key":"10.1016\/j.jpet.2025.103745_bib41","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/s41586-023-06277-0","article-title":"A framework for individualized splice-switching oligonucleotide therapy","volume":"619","author":"Kim","year":"2023","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.jpet.2025.103745_bib42","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3341\/kjo.2024-0031","article-title":"A review of novel medical treatments for thyroid eye disease","volume":"38","author":"Park","year":"2024","journal-title":"Korean J Ophthalmol"},{"issue":"2","key":"10.1016\/j.jpet.2025.103745_bib43","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3390\/biomedicines11020312","article-title":"Graves' eye disease: clinical and radiological diagnosis","volume":"11","author":"Hutchings","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.jpet.2025.103745_bib44","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jtos.2022.02.001","article-title":"Ocular surface disease in thyroid eye disease: a narrative review","volume":"24","author":"Rana","year":"2022","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jpet.2025.103745_bib45","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ajo.2021.05.020","article-title":"Corneal endothelium: a promising quantitative index for graves ophthalmopathy activity evaluation","volume":"230","author":"Zhou","year":"2021","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.jpet.2025.103745_bib46","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13293-016-0089-3","article-title":"Sex-specific phenotypes of hyperthyroidism and hypothyroidism in mice","volume":"7","author":"Rakov","year":"2016","journal-title":"Biol Sex Differ"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356525402584?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356525402584?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T04:58:12Z","timestamp":1768453092000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356525402584"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":46,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0022356525402584"],"URL":"https:\/\/doi.org\/10.1016\/j.jpet.2025.103745","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-IGF-1R antisense oligonucleotide CT102: A promising therapeutic agent for graves' ophthalmopathy","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpet.2025.103745","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103745"}}